Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in October 2013 on request of the sponsor.
On 5 August 2013, orphan designation (EU/3/13/1187) was granted by the European Commission to Gilead Sciences International Ltd, United Kingdom, for idelalisib for the treatment of splenic marginal-zone lymphoma.
For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.
|Disease / condition||
Treatment of splenic marginal-zone lymphoma
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.